Recently developed αC-IN RAF inhibitors11–14,45 (e.g., LY3009120), which have equipotent inhibition for BRAF monomers and dimers with similar efficacy to Ponatinib and promote new RAF dimers due to inhibitor-induced RAF priming, have entered clinical trials in oncogenic BRAF-dependent tumors such as melanoma, colorectal, and other advanced solid tumors. The gene discussed is BRAF; the disease is melanoma.